Data / Form D filings / CONTRAFECT Corp
CONTRAFECT Corp: Form D filings
CONTRAFECT Corp, a biotechnology company in Yonkers, NY, filed 6 Form D notices with the SEC between 2010 and 2015. The latest, on June 25, 2015, reports $20 million sold of a $20 million offering to 9 investors.
Find out what CONTRAFECT Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 28 WELLS AVENUE, 3RD FLOOR, Yonkers, NY, 10701
- Phone
- (914) 207-2300
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1478069
The full lists. Form D filings in New York: 4,357 rows, $123.57, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 25, 2015 | New notice | $20,000,000 | $20,000,000 | $0 | 9 | Jun 12, 2015 | sec.gov |
| Mar 12, 2014 | New notice | Indefinite | $0 | Indefinite | 1 | Feb 24, 2014 | sec.gov |
| Sep 4, 2013 | Amendment | $15,000,000 | $11,963,650 | $3,036,350 | 124 | Jun 18, 2013 | sec.gov |
| Jul 1, 2013 | New notice | $10,000,000 | $9,997,650 | $2,350 | 94 | Jun 18, 2013 | sec.gov |
| Sep 15, 2011 | New notice | $25,000,000 | $12,502,905 | $12,497,095 | 125 | Aug 31, 2011 | sec.gov |
| Aug 23, 2010 | New notice | $10,000,000 | $4,326,603 | $5,673,397 | 6 | Aug 6, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Roger J. Pomerantz, Ph.D. | Director | |
| Cary C. Sucoff | Director | |
| Julia P. Gregory | Executive Officer, Director | |
| Michael J. Otto, Ph.D. | Director | |
| Michael C. Messinger | Executive Officer | |
| Lawrence Yuan Tian, Ph.D. | Director | |
| Sol Barer, Ph.D. | Director | |
| David N. Low, Jr. | Director | |
| Michael C. Wittekind, Ph.D. | Executive Officer | |
| Natalie Yuan Bogdanos | Executive Officer | |
| David C. Scheinberg, M.D., Ph.D. | Director | |
| Isaac C. Blech | Director | |
| Steven C. Gilman, Ph.D. | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Jun 22, 2015 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what CONTRAFECT Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.